
MDxHealth SA (MDXH) Stock Forecast & Price Target
MDxHealth SA (MDXH) Analyst Ratings
Bulls say
MDxHealth is positioned to capitalize on the growing demand for personalized cancer treatment, with its proprietary genomic and molecular technologies. Despite facing short-term financial challenges, the company's recent acquisition of ExoDx and focus on high-margin products sets it up for long-term success and potential profitability in the future. Investors should consider the company's strong track record, strategic decisions, and potential for revenue and profit growth in the coming years when evaluating the stock.
Bears say
MDxHealth is currently facing significant financial and legal challenges, with potential Medicare recoupment payments and a lower revenue forecast. Additionally, while the company has promising portfolio of tests, it has experienced a Q1 miss and decreased its 2026 revenue guidance. Finally, the company's clinical tests such as SelectMDx and ConfirmMDx will face strong competition in the market, and there is uncertainty around the company's ability to achieve sustainable profitability.
This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.
MDxHealth SA (MDXH) Analyst Forecast & Price Prediction
Start investing in MDxHealth SA (MDXH)
Order type
Buy in
Order amount
Est. shares
0 shares